Search
Search Results
-
Nintedanib-associated enterocolitis with intractable diarrhea: a case report
Revised idiopathic pulmonary fibrosis treatment guidelines were published in 2015, and nintedanib was conditionally recommended. Although diarrhea is...
-
Nintedanib in systemic sclerosis treatment: a case report
BackgroundNintedanib was approved for the treatment of scleroderma and scleroderma-related interstitial lung disease, as it decrease the forced...
-
Association between nintedanib adherence trajectory and healthcare use among idiopathic pulmonary fibrosis patients
BackgroundAlthough inverse associations have been found between medication adherence and healthcare use and spending outcomes in many clinical...
-
Clinical significance of high monocyte counts for the continuous treatment with nintedanib
BackgroundNintedanib is now widely used to treat interstitial lung disease (ILD). Adverse events, which occur in not a few patients, make it...
-
Effect of Nintedanib in Patients with Progressive Pulmonary Fibrosis in Subgroups with Differing Baseline Characteristics
IntroductionIn the INBUILD trial in patients with progressive pulmonary fibrosis other than idiopathic pulmonary fibrosis (IPF), nintedanib slowed...
-
A protective role of nintedanib in peritoneal fibrosis through H19–EZH2–KLF2 axis via impeding mesothelial-to-mesenchymal transition
BackgroundPeritoneal fibrosis (PF), a common complication of long-term peritoneal dialysis, accounts for peritoneal ultrafiltration failure to...
-
Real world experience with nintedanib in connective tissue disease-related interstitial lung disease: a retrospective cohort study
Various connective tissue diseases tend to affect specific organs, lungs being the organ with the most serious repercussions and consequences. The...
-
Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis: data from the INBUILD trial
ObjectivesSome patients with rheumatoid arthritis develop interstitial lung disease (RA-ILD) that develops into progressive pulmonary fibrosis. We...
-
A Narrative Review of Real-World Data on the Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
Nintedanib is a tyrosine kinase inhibitor approved for the treatment of idiopathic pulmonary fibrosis (IPF) and other progressive fibrosing...
-
Using group based trajectory modeling for assessing medication adherence to nintedanib among idiopathic pulmonary fibrosis patients
Background and objectiveAdherence to antifibrotic medications has been evaluated in a few studies using annual proportion of days covered (PDC), a...
-
Nintedanib downregulates the profibrotic M2 phenotype in cultured monocyte-derived macrophages obtained from systemic sclerosis patients affected by interstitial lung disease
BackgroundSystemic sclerosis (SSc) is an autoimmune connective tissue disease characterized by vasculopathy and progressive fibrosis of skin and...
-
The effect of nintedanib on lung functions and survival in idiopathic pulmonary fibrosis: real-life analysis of the Czech EMPIRE registry
IntroductionThe antifibrotic drug nintedanib is used for the treatment of idiopathic pulmonary fibrosis (IPF). We analysed the effect of nintedanib...
